Register for our free email digests:
Sawai Pharmaceutical Co., Ltd.
https://www.sawai.co.jp/en/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sawai Pharmaceutical Co., Ltd.
After Ups and Downs, Industry Attempts To Normalize In Q3
After seeing a spike in demand due to the coronavirus pandemic in Q1, with a corresponding dip in Q2, the generics industry has largely seen single-digit drops in net revenues in the third quarter of 2020. Meanwhile, the Indian pharma market has seen recovery after facing a challenging coronavirus-induced slump in the first two quarters of 2020.
Sawai Claims A First With Japanese Pregabalin Launch
Sawai has launched what it says is Japan’s first generic version of Pfizer’s Lyrica pregabalin brand, with other Japanese generics firms waiting in the wings.
Sawai Sets Out US Recalibration
Sawai Pharmaceutical has major plans for its US business that include consolidating its manufacturing operations at a single site and bolstering its pipeline and portfolio, Sawai president Kenzo Sawai tells Generics Bulletin in an exclusive interview.
Sawai Draws On Its Strengths Despite Japanese Pressures
In the face of both local and global pressures, Japan’s Sawai Pharmaceutical is holding steady by relying on its core strengths, company president Kenzo Sawai tells Generics Bulletin in the first part of an exclusive two-part interview.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Other Names / Subsidiaries
-
- Cambridge Biotechnology Ltd (CBT)
- Minster Pharmaceuticals
- Proximagen Group
- Upsher-Smith Laboratories Inc.
- Medisa Shinyaku Inc. and Kaken Shoyaku Inc.